AstraZeneca in AI collaboration with Immunai to inform cancer drug trials

Q: How long will it take to read this news story?

The story "AstraZeneca in AI collaboration with Immunai to inform cancer drug trials" has 255 words across 9 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "AstraZeneca in AI collaboration with Immunai to inform cancer drug trials" was covered 22 hours ago by Channel News Asia, a news publisher based in Singapore.

Q: How trustworthy is 'Channel News Asia' news outlet?

Channel News Asia is a fully independent (privately-owned) news outlet established in 1999 that covers mostly economy and business news. The outlet is headquartered in Singapore and publishes an average of 40 news stories per day. It's most recent story was published 1 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22725658</li><li>URL: https://beamstart.com/news/astrazeneca-in-ai-collaboration-with-1727357258423</li></ul>

Channel News Asia Logo Channel News Asia 22h ago

AstraZeneca in AI collaboration with Immunai to inform cancer drug trials - Channel News Asia

Quick Summary:

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.

FILE PHOTO: The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels, Belgium, January 28, 2021.

Founded in 2018, Immunai uses single-cell genomics, a technique to understand the genetic makeup of single cells, and machine learning to discover and improve the development of novel therapeutics by decoding the immune system.